Sequential infections with rhinovirus and influenza modulate the replicative capacity of SARS-CoV-2 in the upper respiratory tract

Emerg Microbes Infect. 2022 Dec;11(1):412-423. doi: 10.1080/22221751.2021.2021806.

Abstract

Although frequently reported since the beginning of the pandemic, questions remain regarding the impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) interaction with circulating respiratory viruses in coinfected patients. We here investigated dual infections involving early-pandemic SARS-CoV-2 and the Alpha variant and three of the most prevalent respiratory viruses, rhinovirus (RV) and Influenza A and B viruses (IAV and IBV), in reconstituted respiratory airway epithelial cells cultured at air-liquid interface. We found that SARS-CoV-2 replication was impaired by primary, but not secondary, rhino- and influenza virus infection. In contrast, SARS-CoV-2 had no effect on the replication of these seasonal respiratory viruses. Inhibition of SARS-CoV-2 correlated better with immune response triggered by RV, IAV and IBV than the virus entry. Using neutralizing antibody against type I and III interferons, SARS-CoV-2 blockade in dual infections could be partly prevented. Altogether, these data suggested that SARS-CoV-2 interaction with seasonal respiratory viruses would be modulated by interferon induction and could impact SARS-CoV-2 epidemiology when circulation of other respiratory viruses is restored.

Keywords: Alpha variant; SARS-CoV-2; covid-19; influenza virus; interferon; rhinovirus; variants of concern; viral co-infections.

MeSH terms

  • Coinfection / immunology
  • Coinfection / virology*
  • Humans
  • Immunity, Innate
  • Influenza A virus / physiology*
  • Influenza B virus / physiology*
  • Interferons / physiology
  • Respiratory System / virology*
  • Rhinovirus / physiology*
  • SARS-CoV-2 / physiology*
  • Virus Replication / physiology*

Substances

  • Interferons

Grants and funding

This work was supported by the HUG Private Foundation, the Pictet Foundation and the Swiss National Foundation [SNF] under Grant [grant Nr. SNF 31CA30_196644 and 31CA30_196383].